Kyverna Therapeutics Inc
NASDAQ:KYTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kyverna Therapeutics Inc
Cash Interest Paid
Kyverna Therapeutics Inc
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kyverna Therapeutics Inc
NASDAQ:KYTX
|
Cash Interest Paid
415k
|
CAGR 3-Years
262%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Cash Interest Paid
$300m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
5%
|
|
|
Schlumberger NV
NYSE:SLB
|
Cash Interest Paid
$560m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Halliburton Co
NYSE:HAL
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kyverna Therapeutics Inc
Glance View
Kyverna Therapeutics Inc is a US-based company operating in industry. The company is headquartered in Emeryville, California. The company went IPO on 2024-02-08. Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The firm is focused on developing cell therapies for patients suffering from autoimmune diseases. The firm's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). The company intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. The company is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.
See Also
What is Kyverna Therapeutics Inc's Cash Interest Paid?
Cash Interest Paid
142k
Based on the financial report for Dec 31, 2024, Kyverna Therapeutics Inc's Cash Interest Paid amounts to 142k .
What is Kyverna Therapeutics Inc's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 3Y
262%
Over the last year, the Cash Interest Paid growth was -24%. The average annual Cash Interest Paid growth rates for Kyverna Therapeutics Inc have been 262% over the past three years .
